Dear Healthcare Professional,

In 2019, we announced an initiative to transition to a new propellant for our pressurised metered dose inhaler (pMDI) devices, in line with the NHS's timeframe to reduce carbon emissions.[1-3]

As part of our transition to a next-generation propellant for Chiesi pMDIs, we at Chiesi UK have made the decision to optimise our respiratory portfolio and will not transition the following three pMDI products.

1. Clenil® Modulite® (beclometasone) 50 mcg
2. Clenil® Modulite® (beclometasone) 250 mcg
3. Atimos® (formoterol) 12 mcg

The final UK supply of these products will take place in October 2026. All remaining stock is then expected to be exhausted by mid-November, after which the products will be discontinued. The decision to discontinue these products is not due to any stock issues or safety concerns.

**Manufacturing and supply of Clenil 100 mcg and 200 mcg presentations will continue as normal.**

Background:
We have made the decision not to transition these products to the next-generation propellant to align with the latest respiratory treatment guidelines, as suitable alternatives are readily available. This approach will allow for portfolio optimisation by:

- Supporting simplified decision making for prescribers
- Increasing alignment of our product portfolio with UK treatment guidelines
- Reducing environmental impact through streamlined manufacturing and supply-chain activities

Next steps:
For all patients currently prescribed Clenil 50 mcg, Clenil 250 mcg or Atimos 12 mcg, we recommend that their treatment is reviewed to suitable, clinically effective alternatives at the next available patient interaction. We recommend that this review takes place prior to the last date of UK supply, due to take place in October 2026.

## Clenil 100 mcg – an alternative treatment option to Clenil 50 mcg

Due to the overlap between the Clenil 50 mcg and 100 mcg Summary of Product Characteristics (SPC) with regards to therapeutic indication (section 4.1) and posology and method of administrations (section 4.2), we recommend that patients currently taking Clenil 50 mcg are considered for Clenil 100 mcg alternatives, where clinically appropriate.[4,5]

This approach would allow for molecule and device continuity. For example, one puff of Clenil 100 mcg would replace two puffs of Clenil 50 mcg, while maintaining the same therapeutic dose.[4,5]

For appropriate treatment alternatives for Clenil 250 mcg and Atimos 12 mcg, please refer to current UK treatment guidelines.

### Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 009 2329, or at pv.uk@chiesi.com.

### Further Information

For any questions concerning the portfolio optimisation or the discontinuation of Clenil 50 mcg, Clenil 250 mcg and Atimos 12 mcg, please contact Medical Information (medinfo.UK@chiesi.com).

*Please share this information with any UK healthcare professional colleagues who may find it relevant to their clinical practice.*

Kind regards,

**Shish Patel**
Senior Director - Medical Affairs, UK

References:
1. Chiesi. Press release: Chiesi outlines €350 million investment and announces first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD. 12 April 2019.
2. Panigone S, et al. On Drug Delivery. 2020; 106: 14–19.
3. NHS England. Delivering a 'Net Zero' National Health Service. July 2022.
4. Clenil Modulite 50 micrograms Summary of Product Characteristics. Chiesi Limited.
5. Clenil Modulite 100 micrograms Summary of Product Characteristics. Chiesi Limited.